The medicine, called del-desiran, was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and touted as a potential blockbuster
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.